Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InterMune, a biotechnology company, has earned a $15 million development milestone under its development collaboration with Roche for the hepatitis C virus NS3 protease inhibitor compound ITMN-191, currently in a Phase Ib clinical trial in combination with Pegasys and Copegus.
Subscribe to our email newsletter
Under the terms of their 2006 collaboration agreement, the clinical program for ITMN-191 is now being transitioned to Roche which, starting in Phase II, will have primary responsibility for completing the global development and registration program.
In late May 2008, InterMune initiated a 14-day study of ITMN-191 in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). The study is proceeding as planned. Top-line results from the triple combination study are anticipated to be released in the fourth quarter of 2008.
Dan Welch, chairman, CEO and president of InterMune, said: “We look forward to the continued strong relationship with Roche as we together develop protease inhibitor therapies in combination with current standard of care and with other direct antiviral agents.”